Incyte 'downsizing' IDO1 program, ends some combo trials

Incyte Corp. (NASDAQ:INCY) said it is "downsizing" its program evaluating epacadostat, its indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor. The company plans to halt enrollment of six pivotal trials of epacadostat in combination with anti-PD-1 mAbs Keytruda pembrolizumab from

Read the full 378 word article

User Sign In